RLMD Description — Relmada Therapeutics Inc
Relmada Therapeutics is a clinical-stage biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity that addresses areas of medical need in the treatment of central nervous system diseases and other disorders. Co.'s primary product candidate, esmethadone, is being developed as an acting, oral agent for the treatment of depression and other potential indications.